麻将摆出的形状:Dr. Gilbert Wen Invited to be Host and Keynote Speaker for Biomedical Innovation and Entrepreneurshi
|Time：2017-06-10 17:15:44 Form： Writer：|
On June 9, 2017, the second annual conference of the Biomedical Innovation and Entrepreneurship Summit was successfully held in China Medical City, Taizhou, Jiangsu Province. Dr. Gilbert (Xiaoguang) Wen, founder and CEO of Overseas Pharmaceutical, Ltd. (OPL) was invited to host the opening ceremony of the conference. Later, in the forum section, Dr. Wen was invited to give a keynote speech titled: "Using the Development of Controlled-Released Products as an Example to Discuss New Strategies for Novel Drug Development Through FDA 505(b)(2) Regulatory Pathway and CFDA Second Category Drugs.” In the lecture, Dr. Wen presented what and how to fulfill the US FDA 505(b)(2) regulatory pathway and made a comparison between FDA and CFDA polices regarding the regulatory affairs, describing these two classes of innovative medicines waiting to be excavated as a piece of undervalued gold. Dr. Wen demonstrated that over the past ten years, oral controlled-release drugs made up around half of the total new drug approvals (NDA); compared the FDA 505(b)(2) and 505(b) return paths (1) and 505 (J); and finally, Wen also shared with the audience the development process for Lamictal XR, Requip XR and other sustained-release tablets as examples to explain the importance of the development of platform technologies and taking these advanced proprietary technologies for oral controlled-release drugs.
During the evening roadshow section, Dr. Wen showed our project "Controlled-Release Drug Development Platform Technology Application Innovation (NDA/modified drugs),” with a focus on our proprietary platform technologies and the current progress of our product development based on the NDA and ANDA pipelines. We displayed clinical data of new pain-relief product OPL-004, which attracted many investors and pharmaceutical enterprises interested in investment for the new drug development. Afterwards, they approached Dr. Wen and exchanged ideas and engaged in more in-depth discussions. Our company is looking forward to cooperation with these parties in the future.
In the morning, before the opening ceremony, invited guests and experts visited the Overseas Pharmaceutical company headquarters. Dr. Fred (Fengde) Xi, Chief Scientific Officer (CSO) and senior VP, led the tour, introduced the details of the company, and visited the company's R&D laboratory, as well as equipment and facilities.